Skip to main content

Binge Eating Disorder

7
Pipeline Programs
7
Companies
15
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
1
2
3
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

Takeda
VYVANSEApproved
lisdexamfetamine dimesylate
Takeda
oral2017
139M Part D
Jazz Pharmaceuticals
XYREMApproved
sodium oxybate
Jazz Pharmaceuticals
oral2002
98M Part D

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
2 programs
1
Sodium OxybatePHASE_2_3
SolriamfetolPHASE_4
Takeda
TakedaTOKYO, Japan
2 programs
1
VYVANSE(Lisdexamfetamine dimesylate)PHASE_31 trial
VYVANSE(Lisdexamfetamine dimesylate)PHASE_35 trials
Active Trials
NCT01657019Completed604Est. Oct 2014
NCT02009163Completed418Est. Apr 2015
NCT01890785Completed30Est. Aug 2013
+3 more trials
Hope Pharmaceuticals
Hope PharmaceuticalsAZ - Scottsdale
2 programs
1
1
SolriamfetolPhase 41 trial
Sodium OxybatePhase 2/31 trial
Active Trials
NCT00514995Completed15Est. Apr 2011
NCT04602936Unknown64Est. Dec 2024
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
LamotriginePhase 3
Abbott
AbbottABBOTT PARK, IL
1 program
1
sibutraminePhase 31 trial
Active Trials
NCT00402584Completed304
Alliance Pharmaceuticals
1 program
1
Sugar PillPhase 1/21 trial
Active Trials
NCT00904306Completed26Est. Jul 2011
Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
TherapyN/A1 trial
Active Trials
NCT00965705Completed109Est. Mar 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Hope PharmaceuticalsSolriamfetol
TakedaLisdexamfetamine dimesylate
TakedaLisdexamfetamine dimesylate
TakedaLisdexamfetamine dimesylate
TakedaLisdexamfetamine dimesylate
TakedaLisdexamfetamine dimesylate
TakedaLisdexamfetamine dimesylate
TakedaLisdexamfetamine dimesylate
Abbottsibutramine
Hope PharmaceuticalsSodium Oxybate
Alliance PharmaceuticalsSugar Pill
TakedaLisdexamfetamine dimesylate
TakedaLisdexamfetamine dimesylate
TakedaLisdexamfetamine dimesylate
Temple TherapeuticsTherapy

Clinical Trials (15)

Total enrollment: 4,335 patients across 15 trials

NCT04602936Hope PharmaceuticalsSolriamfetol

Solriamfetol in Binge Eating Disorder

Start: Jun 2021Est. completion: Dec 202464 patients
Phase 4Unknown
NCT01328756TakedaLisdexamfetamine dimesylate

Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Start: Jul 2011Est. completion: Sep 2014314 patients
Phase 4Completed
NCT00500071TakedaLisdexamfetamine dimesylate

Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD

Start: Jun 2007Est. completion: Jan 2008318 patients
Phase 4Completed
NCT02009163TakedaLisdexamfetamine dimesylate

Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Start: Jan 2014Est. completion: Apr 2015418 patients
Phase 3Completed
NCT01657019TakedaLisdexamfetamine dimesylate

Open Label Extension in Adults With Binge Eating Disorder (BED)

Start: Aug 2012Est. completion: Oct 2014604 patients
Phase 3Completed
NCT01436175TakedaLisdexamfetamine dimesylate

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

Start: Feb 2012Est. completion: Mar 20141,570 patients
Phase 3Terminated
NCT01106430TakedaLisdexamfetamine dimesylate

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

Start: Jun 2010Est. completion: Jul 2012267 patients
Phase 3Completed
NCT00764868TakedaLisdexamfetamine dimesylate

Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study

Start: Nov 2008Est. completion: Apr 2010269 patients
Phase 3Completed
NCT00402584Abbottsibutramine

A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder

Start: Aug 2000304 patients
Phase 3Completed
NCT00514995Hope PharmaceuticalsSodium Oxybate

Sodium Oxybate in the Treatment of Binge Eating Disorder

Start: Aug 2007Est. completion: Apr 201115 patients
Phase 2/3Completed
NCT00904306Alliance PharmaceuticalsSugar Pill

Binge Eating and Chromium Study

Start: Jul 2008Est. completion: Jul 201126 patients
Phase 1/2Completed
NCT01890785TakedaLisdexamfetamine dimesylate

Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers

Start: Jul 2013Est. completion: Aug 201330 patients
Phase 1Completed
NCT00776555TakedaLisdexamfetamine dimesylate

Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution

Start: Nov 2008Est. completion: Mar 20093 patients
Phase 1Terminated
NCT00746733TakedaLisdexamfetamine dimesylate

Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC

Start: Sep 2008Est. completion: Oct 200824 patients
Phase 1Completed
NCT00965705Temple TherapeuticsTherapy

Stepped Care Treatment for Binge-Eating

Start: Jun 2009Est. completion: Mar 2017109 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.